UMDF and Khondrion Announce The Mito Fund’s Investment in Khondrion to Support Development of One of the Most Advanced Drug Candidates for Primary Mitochondrial Disease
November 21, 2024 07:00 ET
|
Khondrion
21 November 2024 – The United Mitochondrial Disease Foundation’s (UMDF) venture philanthropy arm, The Mito Fund, has invested in Khondrion, a Netherlands-based clinical stage biopharmaceutical company...
Khondrion receives FDA clearance of IND application for pivotal Phase 3 clinical trial of sonlicromanol for the treatment of primary mitochondrial disease
November 14, 2024 07:00 ET
|
Khondrion
Khondrion receives FDA clearance of IND application for pivotal Phase 3 clinical trial of sonlicromanol for the treatment of primary mitochondrial disease 52-week Phase 3 trial to investigate...
Khondrion announces publication in Brain of integrated Phase 2b program demonstrating disease-modifying potential of sonlicromanol in primary mitochondrial disease
November 07, 2024 07:00 ET
|
Khondrion
NIJMEGEN, the Netherlands – 7 November 2024: Khondrion, a clinical stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial disease (PMD), today announced...
Khondrion appoints Jasper Levink as Chief Financial and Business Officer
September 11, 2024 07:00 ET
|
Khondrion
Khondrion appoints Jasper Levink as Chief Financial and Business Officer NIJMEGEN, the Netherlands – 11 September 2024: Khondrion, a clinical stage biopharmaceutical company discovering and...
Khondrion announces sonlicromanol Phase IIb progress supporting Phase III development in MELAS spectrum disorders
November 22, 2022 07:00 ET
|
Khondrion
Khondrion announces sonlicromanol Phase IIb progress supporting Phase III development in MELAS spectrum disorders Sonlicromanol for MELAS spectrum disorders – a rare, progressive primary...
Khondrion announces sonlicromanol Phase IIb progress supporting Phase III development in MELAS spectrum disorders
November 22, 2022 02:00 ET
|
Khondrion
Khondrion announces sonlicromanol Phase IIb progress supporting Phase III development in MELAS spectrum disorders Sonlicromanol for MELAS spectrum disorders – a rare, progressive primary...
Khondrion completes enrolment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with MELAS spectrum disorders
January 10, 2022 02:00 ET
|
Khondrion
Khondrion completes enrolment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with MELAS spectrum disorders NIJMEGEN, the Netherlands – 10 January 2022: Khondrion, a...
Khondrion announces first patients dosed in 6-month paediatric Phase II study of sonlicromanol for mitochondrial diseases
April 21, 2021 07:00 ET
|
Khondrion
Khondrion announces first patients dosed in 6-month paediatric Phase II study of sonlicromanol for mitochondrial diseases Study will examine the pharmacokinetics, safety and efficacy of...
Khondrion receives EMA agreement on its Paediatric Investigation Plan for sonlicromanol
January 18, 2021 02:00 ET
|
Khondrion
Khondrion receives EMA agreement on its Paediatric Investigation Plan for sonlicromanol NIJMEGEN, the Netherlands – 18 January, 2021: Khondrion, a clinical-stage biopharmaceutical company...
Khondrion Receives Rare Pediatric Disease Designation for Sonlicromanol from US FDA
September 28, 2020 07:00 ET
|
Khondrion
Khondrion Receives Rare Pediatric Disease Designation for Sonlicromanol from US FDA Designation granted for the treatment of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like...